Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Harris, J. T.
Right arrow Articles by Thornton, J. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Harris, J. T.
Right arrow Articles by Thornton, J. E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Alcohol and Alcoholism Vol. 35, No. 4, pp. 319-323, 2000
© 2000 Medical Council on Alcoholism

Review

A ROLE FOR VALPROATE IN THE TREATMENT OF SEDATIVE–HYPNOTIC WITHDRAWAL AND FOR RELAPSE PREVENTION

John T. Harris, John D. Roache and Joseph E. Thornton

Department of Psychiatry, Division of Alcohol and Drug Addiction, The University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78284-7953, USA

Received 11 November 1999; in revised form 7 February 2000; accepted 22 February 2000

ABSTRACT

In the human central nervous system, the gamma-aminobutyric acid (GABA) type A receptor complex undergoes changes with both acute and chronic exposure to sedative–hypnotic drugs. These changes contribute to both the acute effects of these drugs as well as the chronic effects of sedative–hypnotic dependence, withdrawal, and drug craving. Clinically these chronic effects are difficult to treat in patients dependent on ethanol or benzodiazepines. Valproate may return the GABA type A receptor function to a state more closely resembling its normal function. By this mechanism, it is possible to reduce the symptoms of sedative–hypnotic withdrawal and relapse.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
L. R. McMahon and C. P. France
Discriminative Stimulus Effects of Positive GABAA Modulators and Other Anxiolytics, Sedatives, and Anticonvulsants in Untreated and Diazepam-Treated Monkeys
J. Pharmacol. Exp. Ther., January 1, 2003; 304(1): 109 - 120.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.